Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs

Papa, G.; Fedele, V.; Chiavetta, A.; Lorenti, I.; Leotta, C.; Luca, S.; Rabuazzo, A. M.; Piro, S.; Alagona, C.; Spadaro, L.; Purrello, F.; Pezzino, V.
March 2008
Acta Diabetologica;Mar2008, Vol. 45 Issue 1, p53
Academic Journal
Glycemic control in elderly persons with type 2 diabetes mellitus (T2DM) is challenging because they are more likely to have other age-associated medical conditions and to experience hypoglycemia during intensive therapy. A best therapeutic strategy for these patients has not yet been defined. We investigated the efficacy and safety of adding once-daily insulin glargine to patients’ current oral antidiabetic drugs (OAD) regimen, compared to increasing the OAD doses. The study enrolled patients aged 65 years or more, with poor glycemic control. Patients were randomized to two groups and entered a 3-week titration period in which their actual therapy was adjusted to meet the study’s glycemic goals, by either adding insulin glargine to current therapy (group A, 27 patients) or increasing current OAD dosages (group B, 28 patients). Thereafter, therapies were continued unchanged for a 24-week observation period. The mean therapeutic dosage of insulin glargine in group A was 14.9 IU/day (SD = 5.0 IU/day). During the observation period, mean levels of glycosylated hemoglobin (HbA1c) reduced by 1.5% in group A and 0.6% in group B ( P = 0.381). An HbA1c level <7.0% was achieved by five patients in each group. Mean fasting blood glucose levels reduced by 29 and 15% in groups A and B, respectively ( P = 0.029). Group A had fewer total hypoglycemic events (23 vs. 79, P = 0.030) and fewer patients experiencing any such event (9 vs. 17, P = 0.045). Neither a serious hypoglycemic event nor other adverse event occurred. These results suggest that, compared to increasing OAD dosage, the addition of insulin glargine to current OAD therapy is as effective but safer in terms of the risk for hypoglycemia in elderly patients with T2DM.


Related Articles

  • Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer. Colca, J R; VanderLugt, J T; Adams, W J; Shashlo, A; McDonald, W G; Liang, J; Zhou, R; Orloff, D G // Clinical Pharmacology & Therapeutics;Apr2013, Vol. 93 Issue 4, p352 

    It may be possible to achieve insulin sensitivity through the recently identified mitochondrial target of thiazolidinediones (mTOT), thereby avoiding peroxisome proliferator-activated receptor-γ (PPAR-γ)-dependent side effects. In this phase IIb clinical trial, 258 patients with type 2...

  • Effects of Exercise and Caloric Restriction on Insulin Resistance and Cardiometabolic Risk Factors in Older Obese Adults-A Randomized Clinical Trial. Yassine, Hussein N.; Christine M. Marchetti; Krishnan, Raj K.; Vrobel, Thomas R.; Gonzalez, Frank; Kirwan, John P. // Journals of Gerontology Series A: Biological Sciences & Medical ;Jan2009, Vol. 64A Issue 1, p90 

    Background. The prevalence of insulin resistance, metabolic syndrome, and cardiovascular disease is greatest in older obese patients, and effective evidence-based treatment strategies are lacking. Methods. A prospective controlled study was conducted on 24 older (65.5 ± 5.0 years) obese (body...

  • Pioglitazone is Effective Therapy for Elderly Patients with Type 2 Diabetes Mellitus. Rajagopalan, Rukmini; Perez, Alfonso; Ye, Zhan; Khan, Mehmood; Murray, Frederick T. // Drugs & Aging;2004, Vol. 21 Issue 4, p259 

    Pioglitazone as monotherapy and in combination with sulfonylurea, metformin, or insulin has consistently demonstrated improved glycaemic and lipid parameters in patients with type 2 diabetes mellitus. Objective: We performed a subanalysis to examine the effect of pioglitazone on glycaemia and...

  • Diabetes treatment without weight gain.  // Pharmaceutical Technology Europe;Sep2006, Vol. 18 Issue 9, p16 

    The article reports on the presentation of the results of a clinical trial of Levemir, a novel diabetes drug, at the American Diabetes Association congress in Washington D.C. In a study of more than 1,000 people, Levemir showed promising results for diabetes control without weight gain. The drug...

  • Basal Supplementation of Insulin Lispro Protamine Suspension Versus Insulin Glargine and Detemir for Type 2 Diabetes. ESPOSITO, KATHERINE; PETRIZZO, MICHELA; CHIODINI, PAOLO; ROSARIA IMPROTA, MARIA; CAPUANO, ANNALISA; GIUGLIANO, DARIO // Diabetes Care;Dec2012, Vol. 35 Issue 12, p2698 

    OBJECTIVE-We compared the effect of insulin lispro protamine suspension (ILPS) with that of insulin glargine and insulin detemir, all given as basal supplementation, in the treatment of patients with type 2 diabetes. RESEARCH DESIGN AND METHODS-We conducted an electronic search until February...

  • Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients. Aziz, Kamran M. A. // Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;2015, Vol. 8, p207 

    Diabetes management during Ramadan fasting is challenging to the physician in terms of minimizing the risk of hypoglycemia. As compared to oral hypoglycemic agents (OHAs) and sulfonylureas (SUs), which carry a higher and significant risk of hypoglycemia, newer antidiabetic agents such as...

  • Are you overdosing yourself? Deas, Gerald W. // New York Amsterdam News;2/14/2002, Vol. 93 Issue 7, p17 

    This author focuses on the case of a 76-year-old diabetic patient with a five-year history of diabetes and problems faced by her due to double-dosage of drugs. Her case had been followed by a private physician as well as a physician in the local hospital clinic. She was well controlled on oral...

  • Trials That Matter: Rosiglitazone, Ramipril, and the Prevention of Type 2 Diabetes. Nathan, David M. // Annals of Internal Medicine;3/20/2007, Vol. 146 Issue 6, p461 

    The article focuses on the development of the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication trial. This trial is designed to identify if ramipril and rosiglitazone could prevent type 2 diabetes. Both drugs are generally safe and had a low frequency of severe adverse...

  • (How) Can We Prevent Type 2 Diabetes? Buchanan, Thomas A. // Diabetes;Jun2007, Vol. 56 Issue 6, p1502 

    The article offers ways to prevent type 2 diabetes and present the pathogenesis of the disease. Randomized controlled trials were conducted to test the impact of behavioral and pharmacological interventions on rates of development of this disease on high-risk groups. In this type of diabetes,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics